Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Servier buys into MacroGenics' Phase I anticancer MAb

This article was originally published in Scrip

Executive Summary

Servier is to pay an initial $20 million to Rockville, Maryland-based privately held biotech firm MacroGenics to access the latter's MGA271, an Fc-optimised therapeutic monoclonal antibody that targets the immune regulator B7-H3 and is in Phase I trials to treat solid tumours.


Related Content

MacroGenics Signs Another Lucrative DART Deal with Janssen For $75m Up Front


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts